Clinical trial · Interventional
Lattice Radiotherapy for Adults With Large Tumors
Pilot Study of Lattice Radiotherapy in Adults With Large Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 9, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260909-000002
Summary
Brief summary (as posted)
The purpose of this study is to ask whether using a specialized radiation therapy technique called Lattice Radiation Therapy (LRT) can shrink large tumors when given with palliative radiation therapy. The primary questions are: * if LRT is safe and does not worsen existing side effects or cause new side effects * if adding LRT to standard radiation therapy can improve tumor shrinkage. Participants will have one additional radiation treatment (LRT) prior to starting palliative radiation and then their progress will be followed for one year.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Large Tumor | — | UNRESOLVED | — |
| Palliative Radiotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lattice Radiation Therapy (LRT) | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Lattice Radiation Therapy (LRT)
- description
- Participants will receive one additional dose of Intensity-Modulated Radiation Therapy (IMRT) called Lattice Radiation Therapy (LRT) prior to starting regular palliative radiation therapy.
- interventionNames
- Radiation: Lattice Radiation Therapy (LRT)
Primary outcomes (1)
- measure
- Incidence of Radiotherapy (RT) treatment-related, non-hematologic Common Terminology Criteria for Adverse Events (CTCAE) v6.0 Grade ≥ 3 toxicity and Adverse Events of Special Interest (AESI) at 90 days
- timeFrame
- 90 days
- description
- Incidence reported as the number of events divided by the study population.
Secondary outcomes (3)
- measure
- Incidence of Radiotherapy (RT) treatment-related, non-hematologic CTCAE v6.0 Grade ≥ 3 toxicity and Adverse Events of Special Interest (AESI) at 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed malignancy diagnosis * Radiographic evidence of large extracranial tumor (≥ 4.5 cm) * Patients with primary or metastatic extracranial tumors may be included * Planned to undergo palliative radiation treatment * Life expectancy of at least 3 months * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3 * Patient must sign study-specific informed consent Exclusion Criteria: * Primary lesion with radiosensitive histology (i.e. germ cell tumors, lymphoma, leukemia, and multiple myeloma) * Prior radiation treatment that overlaps with any planned site of protocol radiotherapy that would preclude further palliative RT. * Receiving concurrent cytotoxic cancer therapy regimens or Vascular Endothelial Growth Factor (VEGF) inhibitor that would overlap with LRT administration. Cytotoxic chemotherapy, targeted therapies, small molecule inhibitors, or sVEGF inhibitors prior to radiation treatment or planned after radiation delivery are allowed at the discretion of the treating radiation oncologist.
References
Publications (0)
Data not yet available